Regenxbio Inc (NASDAQ:RGNX) SVP Curran Simpson sold 21,890 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $30.04, for a total value of $657,575.60. Following the sale, the senior vice president now owns 41,390 shares in the company, valued at $1,243,355.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Curran Simpson also recently made the following trade(s):
- On Monday, December 4th, Curran Simpson sold 110 shares of Regenxbio stock. The shares were sold at an average price of $30.00, for a total value of $3,300.00.
- On Monday, November 27th, Curran Simpson sold 2,000 shares of Regenxbio stock. The shares were sold at an average price of $29.31, for a total value of $58,620.00.
Shares of Regenxbio Inc (RGNX) traded up $1.45 during midday trading on Monday, reaching $31.75. The company’s stock had a trading volume of 325,700 shares, compared to its average volume of 278,419. Regenxbio Inc has a fifty-two week low of $16.30 and a fifty-two week high of $36.10.
Regenxbio (NASDAQ:RGNX) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.04. The business had revenue of $1.34 million for the quarter. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. equities analysts predict that Regenxbio Inc will post -2.71 earnings per share for the current fiscal year.
A number of research firms recently issued reports on RGNX. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research note on Monday. TheStreet lowered Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. Evercore ISI began coverage on Regenxbio in a research note on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective on the stock. Zacks Investment Research lowered Regenxbio from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, BidaskClub upgraded Regenxbio from a “hold” rating to a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $42.43.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc increased its stake in Regenxbio by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 2,011 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in Regenxbio in the 3rd quarter worth about $328,000. Ardsley Advisory Partners bought a new position in Regenxbio in the 2nd quarter worth about $197,000. Voya Investment Management LLC bought a new position in shares of Regenxbio during the 2nd quarter valued at about $249,000. Finally, Asymmetry Capital Management L.P. increased its position in shares of Regenxbio by 12.2% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 1,508 shares during the last quarter. Institutional investors and hedge funds own 68.73% of the company’s stock.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc and related companies with MarketBeat.com's FREE daily email newsletter.